Live Updates: COVID-19 Cases
  • World 30,982,249
    World
    Confirmed: 30,982,249
    Active: 7,438,296
    Recovered: 22,582,580
    Death: 961,373
  • USA 6,967,403
    USA
    Confirmed: 6,967,403
    Active: 2,539,886
    Recovered: 4,223,693
    Death: 203,824
  • India 5,398,230
    India
    Confirmed: 5,398,230
    Active: 1,011,732
    Recovered: 4,299,724
    Death: 86,774
  • Brazil 4,528,347
    Brazil
    Confirmed: 4,528,347
    Active: 571,687
    Recovered: 3,820,095
    Death: 136,565
  • Russia 1,097,251
    Russia
    Confirmed: 1,097,251
    Active: 171,450
    Recovered: 906,462
    Death: 19,339
  • Peru 762,865
    Peru
    Confirmed: 762,865
    Active: 123,659
    Recovered: 607,837
    Death: 31,369
  • Mexico 694,121
    Mexico
    Confirmed: 694,121
    Active: 124,639
    Recovered: 496,224
    Death: 73,258
  • South Africa 659,656
    South Africa
    Confirmed: 659,656
    Active: 54,282
    Recovered: 589,434
    Death: 15,940
  • Spain 659,334
    Spain
    Confirmed: 659,334
    Active: 628,839
    Recovered: ?
    Death: 30,495
  • Chile 444,674
    Chile
    Confirmed: 444,674
    Active: 14,319
    Recovered: 418,101
    Death: 12,254
  • France 442,194
    France
    Confirmed: 442,194
    Active: 319,346
    Recovered: 91,574
    Death: 31,274
  • Iran 419,043
    Iran
    Confirmed: 419,043
    Active: 37,293
    Recovered: 357,632
    Death: 24,118
  • UK 390,358
    UK
    Confirmed: 390,358
    Active: 348,599
    Recovered: ?
    Death: 41,759
  • Bangladesh 347,372
    Bangladesh
    Confirmed: 347,372
    Active: 88,073
    Recovered: 254,386
    Death: 4,913
  • Saudi Arabia 329,271
    Saudi Arabia
    Confirmed: 329,271
    Active: 15,383
    Recovered: 309,430
    Death: 4,458
  • Pakistan 305,031
    Pakistan
    Confirmed: 305,031
    Active: 6,572
    Recovered: 292,044
    Death: 6,415
  • Turkey 301,348
    Turkey
    Confirmed: 301,348
    Active: 27,786
    Recovered: 266,117
    Death: 7,445
  • Italy 296,569
    Italy
    Confirmed: 296,569
    Active: 43,161
    Recovered: 217,716
    Death: 35,692
  • Germany 272,308
    Germany
    Confirmed: 272,308
    Active: 19,342
    Recovered: 243,500
    Death: 9,466
  • Canada 142,774
    Canada
    Confirmed: 142,774
    Active: 9,376
    Recovered: 124,187
    Death: 9,211
  • Netherlands 91,934
    Netherlands
    Confirmed: 91,934
    Active: 85,659
    Recovered: ?
    Death: 6,275
  • China 85,279
    China
    Confirmed: 85,279
    Active: 168
    Recovered: 80,477
    Death: 4,634
  • Australia 26,897
    Australia
    Confirmed: 26,897
    Active: 2,081
    Recovered: 23,967
    Death: 849
  • S. Korea 22,975
    S. Korea
    Confirmed: 22,975
    Active: 2,434
    Recovered: 20,158
    Death: 383
  • New Zealand 1,811
    New Zealand
    Confirmed: 1,811
    Active: 67
    Recovered: 1,719
    Death: 25

Remdesivir, tocilizumab considered for ‘restricted use’ on severely ill COVID-19 patients

Author at TechGenyz Health
Drug
A Person Holding Drug In His Hands. @EMA_News/Twitter

Anti-viral drug Remdesivir and tocilizumab, an immunomodulator, are being considered for “restricted use” on severely ill COVID-19 patients on “emergency and compassionate grounds”, according to revised clinical management guidelines to be released soon.

The much-touted anti-malarial drug hydroxychloroquine will continue to be used while Azythromycin may be dropped from the treatment protocol, sources in the know of the developments told PTI.

A clinical management guideline issued on March 31 had recommended the use of hydroxychloroquine in combination with azithromycin on COVID-19 patients who require ICU management.

“Since COVID-19 is a new disease and there is no drug or vaccine for it as of now, treatment protocols are being revised from time to time based on emerging evidences,” a source said.

Tocilizumab, an immunomodulatory drug that modifies the immune system or its functioning, will be used on experimental basis. Based on evidence, some more drugs to be used in combination with hydroxychloroquine may be added to the protocol, but no consensus has been reached regarding them as yet, the source said.

The new clinical management guidelines for COVID-19 is in the process of being finalised by the experts of the National Task Force on COVID-19, which last held its meeting on Sunday.

India’s drug regulator had last week granted US pharma giant Gilead Sciences the marketing authorisation for its drug remdesivir for “restricted emergency use” on hospitalised COVID-19 in the country, sources said.

The approval process for remdesivir was accelerated in view of the emergency situation and the unmet need for medicines in light of the coronavirus outbreak.

“This medicine, which is administered in the form of an injection, has been approved to be sold by retail on the prescription of specialists for use in a hospital or in institutional set-up only. It has been approved for use for a maximum of five days,” a source said.

India currently does not manufacture Remdesivir. The four companies – Hetero, Jubilant Life Sciences, Cipla, and Mylan NV – with which Gilead Sciences Inc has entered into non-exclusive licensing agreements are still awaiting permission from the Drug Controller General of India (DCGI) for manufacturing and distribution remdesivir in the country.

Remdesivir has been issued an Emergency Use Authorization (EUA) by the United States Food and Drug Administration (FDA) for the treatment of hospitalized patients with severe COVID-19 illness.

Career

Subscribe